WithdrawnPhase 1NCT06291415
The Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HMPL-523 in Adult Subjects With Immune Thrombocytopenia (ITP)
Studying Autoimmune thrombocytopenia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Hutchmed
- Principal Investigator
- William Schelman, MD, PhDHutchmed
- Intervention
- HMPL-523(drug)
- Eligibility
- 18 years · All sexes
- Timeline
- 2024 – 2026
Study locations (28)
- Childrens Hospital of California, Irvine, California, United States
- Georgetown University Medical Center - Georgetown Lombardi Comprehensive Cancer Center, Georgetown, Delaware, United States
- Center for Cancer and Blood Disorders, Bethesda, Maryland, United States
- Massachusetts General Hospital, Boston, Massachusetts, United States
- San Juan Oncology Associates, Farmington, New Mexico, United States
- East Carolina University, Brody School of Medicine, Greenville, North Carolina, United States
- Taussig Cancer Institute, Cleveland, Ohio, United States
- Oklahoma Cancer Specialists and Research Institute, Tulsa, Oklahoma, United States
- Texas Oncology San Antonio Medical Center, San Antonio, Texas, United States
- University of Washington (UW) Medical Center, Seattle, Washington, United States
- Peninsula Private Hospital, Frankston, Victoria, Australia
- The Perth Blood Institute (PBI) Hollywood Specialist Centre, West Perth, Western Australia, Australia
- Royal Adelaide Hospital, Adelaide, Australia
- Canberra Hospital, Canberra, Australia
- Charite university, Berlin, Germany
- +13 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06291415 on ClinicalTrials.govOther trials for Autoimmune thrombocytopenia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07559331High-Dose Dexamethasone Combined With Orelabrutinib Versus High-Dose Dexamethasone Combined With Placebo in Adult Patients With Newly Diagnosed Primary Immune ThrombocytopeniaShandong University
- RECRUITINGPHASE2NCT07362238Daratumumab Versus Rituximab in the Management of Pediatric Primary Immune Thrombocytopenia (ITP)Institute of Hematology & Blood Diseases Hospital, China
- RECRUITINGPHASE2NCT07362199Anti-CD38 Monoclonal Antibody Combined With Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)Institute of Hematology & Blood Diseases Hospital, China
- RECRUITINGEARLY PHASE1NCT07441525UCAR-T Targeting CD19/BCMA in Subjects With Autoantibody-Mediated Autoimmune Benign Hematological DiseasesUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology
- RECRUITINGPHASE2NCT07234019Rituximab Combining Anti-CD38 Monoclonal Antibody Versus Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)Institute of Hematology & Blood Diseases Hospital, China
- RECRUITINGPHASE2NCT07297563Anti-CD38 Monoclonal Antibody Versus Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)Institute of Hematology & Blood Diseases Hospital, China
- RECRUITINGPHASE2NCT07294365A Study of DZD8586 in Adults With Primary Immune Thrombocytopenia (ITP) (TAI-SHAN11)Dizal Pharmaceuticals
- RECRUITINGPHASE2NCT07104565Study to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell DisordersIncyte Corporation